Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWO…

Overview of attention for article published in Journal of Patient-Reported Outcomes, June 2018

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 16 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 425 followers.

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). https://t.co/GhdR7JIMSa https://t.co/PT8KMtt4

29 Jun 2018

Reply Repost Favourite

29 Jun 2018

Reply Repost Favourite